Nymox (NASDAQ: NYMX) Has Global Patent Rights for Statin Drugs for the
Treatment and Prevention of Alzheimer's Disease
HASBROUCK HEIGHTS, N.J., August 29 /CNW/ - In a newly published brain
disease study quoted on the front page of the Wall Street Journal and
elsewhere, scientists for the first time have found evidence showing an
association between statin use and a lower risk of neuropathologic changes in
the brain associated with Alzheimer's disease (AD) (Neurology August,
2007;69;878-885). Researchers at the University of Washington, the Veterans
Affairs Puget Sound Health Care System and the Group Health Cooperative of
Puget Sound reviewed autopsies on 110 patients who had died in the course of a
long term community-based study on cognitive changes in the elderly. After
controlling for age and other factors, they found that the brains of statin
users showed significantly reduced risk of having the typical signs of
Alzheimer's disease than nonusers, including a more than twofold reduction in
the risk of having one of the major hallmarks of AD (neurofibrillary tangles).
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) holds U.S. and global
patent rights for the use of statin drugs for the prevention and treatment of
AD, including for patients at risk for AD because of vascular-related risk
factors or disease.
Statins are widely used cholesterol-lowering drugs with a
well-established track record of safety. They have an estimated global market
over $25 billion and have attracted wide attention both in the medical
literature and in the media as a potential new way of treating or preventing
Alzheimer's disease. Alzheimer's disease is the leading cause of dementia in
the elderly, afflicting an estimated 4.5 million people in the U.S.
Research is ongoing into statins and their possible effects on the AD
disease process and potential use for the prevention or treatment of AD.
Recent scientific studies and reviews include CNS Drugs. 2007;21:449-62;
Neurosci Lett. 2007; 416:279-84; Curr Med Chem. 2007;14:103-12; Expert Opin
Investig Drugs. 2006;15:1479-85; Neurol Res. 2006; 28:630-6; and Acta Neurol
Scand 2006; 114 (Suppl. 185): 3-7, 63-70, 78-86, 87-92. Earlier studies into
the association between statin use and lower risk of AD have shown conflicting
results: see Arch Neurol 2000;57:1439-1443; Lancet 2000;356:1627-1631; Arch
Neurol 2002;59:223-227; Arch Neurol 2002;59:378-384; Lancet 2002;360:7-22;
Lancet 2002;360:1623-1630; Neurology 2004;63:1624-1628; Arch Gen Psychiatry
2005;62:217-224; Arch Neurol 2005;62:1047-1051.
More information about Nymox is available at www.nymox.com, email:
firstname.lastname@example.org, or 800-936-9669.
This press release contains certain "forward-looking statements" as
defined in the United States Private Securities Litigation Reform Act of 1995
that involve a number of risks and uncertainties. There can be no assurance
that such statements will prove to be accurate and the actual results and
future events could differ materially from management's current expectations.
The conduct of clinical trials and the development of drug products involve
substantial risks and uncertainties and actual results may differ materially
from expectations. Promising early results do not ensure that later stage or
larger scale clinical trials will be successful or will proceed as expected.
Such factors are detailed from time to time in Nymox's filings with the United
States Securities and Exchange Commission and other regulatory authorities.
For further information:
For further information: Nymox Pharmaceutical Corporation Roy Wolvin,